endometrial disorders. malignant neoplasm of female genital organs
Conditions
Interventions
Intervention 1: Intervention: letrozol, tablet 2.5 mg, one time daily, three months. Intervention 2: Control group: routin treatment, megestrol, tablet 40mg, three months.
Treatment - Drugs
Intervention: letrozol, tablet 2.5 mg, one time daily, three months
Control group: routin treatment, megestrol, tablet 40mg, three months
Sponsors
Women's Reproductive Health Research Center, Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Women with Abnormal Uterine Bleeding and Disordered proliferative endometrium or Simple hyperplasia; 2- the desire to participate in the study. Exclusion criteria: 1- persons sensitive to letrozole; 2- Severe impairment of liver function; 3- uncontrolled hypertension; 4- thromboembolism
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endometrial histology. Timepoint: before intervention, three months after intervention. Method of measurement: endometrial biopsia. | — |
Secondary
| Measure | Time frame |
|---|---|
| Flashing. Timepoint: during 3 months. Method of measurement: questionnaire.;Chest pain & dyspnea. Timepoint: during three months. Method of measurement: questionnaire.;Headeche. Timepoint: during 3 months. Method of measurement: questionnaire.;Insomnia. Timepoint: during 3 months. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Parvin Mostafa Gharebaghi
Women's Reproductive Health Research Center, Tabriz University of Medical Sciences
Outcome results
None listed